Roche Ends Development of Several Drugs

Among them, lampalizumab had fared poorly in phase 3 tests

In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates.

The casualties:

  • Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy due to age-related macular degeneration (AMD) and secondary to AMD. At one point, some analysts had predicted the drug could reach $2 billion in annual sales.
  • RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma that was in phase 1 testing.
  • RG6047, which was being tested in phase 1 for metastatic estrogen receptor-positive, HER2-negative breast cancer.
  • RG7203, a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

Source: FierceBiotech; February 1, 2018.